The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset

References

• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297‒1303. doi:10.1136/bmj.320.7245.1297
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23(5):698‒702. doi:10.1183/09031936.04.00121404
   PubMed Web of Science ®Google Scholar
• Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease: a systematic review. Am J Respir Crit Care Med. 2021;203(6):689‒698. doi:10.1164/rccm.202005-1854OC
   Web of Science ®Google Scholar
• Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(8):943‒950. doi:10.1164/rccm.201412-2269OC
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3):1602265. doi:10.1183/13993003.02265-2016
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5):398–401. doi:10.1378/chest.117.5_suppl_2.398S
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed August 3, 2022.
   Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337‒344. doi:10.1016/S2213-2600(18)30102-4
   Web of Science ®Google Scholar
• Jones PW, Anderson JA, Calverley PM, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011;12(1):71. doi:10.1186/1465-9921-12-71
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662‒671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Vestbo J, Anderson JA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med. 2017;195(7):881‒888. doi:10.1164/rccm.201607-1421OC
   Web of Science ®Google Scholar
• Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1297‒1308. doi:10.2147/COPD.S153631
   Web of Science ®Google Scholar
• Labonté LE, Tan WC, Li PZ, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285‒298. doi:10.1164/rccm.201509-1795OC
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374(19):1811‒1821. doi:10.1056/NEJMoa1505971
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Wedzicha JA, Iversen M, et al. RESTORE group. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50(4):1700711. doi:10.1183/13993003.00711-2017
   PubMed Web of Science ®Google Scholar
• Calverley PM, Page C, Dal Negro RW, et al. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019;14:2733‒2744. doi:10.2147/COPD.S221852
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327. doi:10.1164/ajrccm/145.6.1321
   PubMed Web of Science ®Google Scholar
• Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2:75–79. doi:10.1081/COPD-200050513
   PubMedGoogle Scholar
• Sun Y, Zhou J. New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019;14:1119‒1125. doi:10.2147/COPD.S205382
   Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222‒2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled analysis of the TONADO/DYNAGITO trials. Adv Ther. 2020;37(10):4266‒4279. doi:10.1007/s12325-020-01438-3
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117‒126. doi:10.1016/S2213-2600(18)30006-7
   Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018;198(10):1268‒1278. doi:10.1164/rccm.201712-2493OC
   Web of Science ®Google Scholar
• Dal Sasso M, Bovio C, Culici M, Braga PC. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002;28(2–3):75‒82.
   Google Scholar
• Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2007;1(3):307‒316. doi:10.1586/17476348.1.3.307
   PubMedGoogle Scholar
• Ricevuti G, Mazzone A, Uccelli E, Gazzani G, Fregnan GB. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988;43:585‒590. doi:10.1136/thx.43.8.585
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387‒395. doi:10.1136/thx.2003.008730
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5(1):44‒49. doi:10.1111/j.1752-699X.2010.00198.x
   PubMed Web of Science ®Google Scholar